Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.

World journal of gastroenterology - 28 Jan 2006

Furusyo Norihiro, Takeoka Hiroaki, Toyoda Kazuhiro, Murata Masayuki, Tanabe Yuichi, Kajiwara Eiji, Shimono Junya, Masumoto Akihide, Maruyama Toshihiro, Nomura Hideyuki, Nakamuta Makoto, Takahashi Kazuhiro, Shimoda Shinji, Azuma Koichi, Sakai Hironori, Hayashi Jun

Abstract excerpt

AIM: To determine the efficacy of long-term lamivudine treatment of a large number of Japanese patients with chronic hepatitis B. METHODS: In this retrospective, multi-center trial, 318 Japanese patients with chronic hepatitis B received 100 mg of lamivudine daily for up to 36 (median 21) mo. Virological response was a decline to a serum HBV DNA level less than 3.7 log copies/mL. Virological breakthrough was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alanine Transaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to DNA, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Lamivudine

Source

Open in PubMed Open full text

Identifiers

PMID: 16489669
DOI: 10.3748/wjg.v12.i4.561
PMCID: PMC4066088

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term lamivudine treatment for chronic hepatitis B in Japanese patients: a project of Kyushu University Liver Disease Study.PMID 16489669Read ↗

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.Semantic proximity Read ↗

Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients.Semantic proximity Read ↗

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.Semantic proximity Read ↗

Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares.Semantic proximity Read ↗

Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment.Semantic proximity Read ↗

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.Semantic proximity Read ↗

Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.Semantic proximity Read ↗

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.Semantic proximity Read ↗

Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.Semantic proximity Read ↗

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.Semantic proximity Read ↗

Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.